VA
HOWL icon

Verdad Advisers’s Werewolf Therapeutics HOWL Stock Holding History

Verdad Advisers’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Buy
348,709
+318,949
+1,072% +$194K 0.12% 175
2026
Q1 		$24.8K Buy
+29,760
New +$20.4K 0.03% 177

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Verdad Advisers's HOWL Position: Q2 2026 in Review

Verdad Advisers increased its Werewolf Therapeutics (HOWL) stake by 1,072% in Q2 2026, buying an estimated $194K and bringing the position to 348,709 shares worth $126K. The position accounts for 0.12% of the portfolio, ranked #175.

Verdad Advisers first reported a position in HOWL in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Verdad Advisers held 348,709 shares of Werewolf Therapeutics worth $126K as of Q2 2026.
  • Verdad Advisers bought 318,949 Werewolf Therapeutics shares in Q2 2026, an estimated $194K.
  • Werewolf Therapeutics made up 0.12% of Verdad Advisers's portfolio in Q2 2026, its #175 holding.
  • Verdad Advisers first reported a position in Werewolf Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.